Codexis Investor Relations Material
Latest events
Status Update
Codexis
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Codexis Inc
Access all reports
Segment Data
Access more data
Revenue by
Business area
Performance Enzymes
Novel Biotherapeutics
Expenses by
Financials
Codexis, Inc. discovers, develops, and sells enzymes and other proteins to the pharmaceutical and renewable chemical industries. The company offers CodeEvolver protein engineering platform that involves designing of molecule, designing an enzyme to do the job, and optimizing the enzyme for industrial use in discovery drug safety evaluations (DSEs) market; CodeXyme enzyme for converting sugar into specialty chemicals; and enzymes for manufacturing APIs. It also provides enzymes for fuel ethanol industry.
Key slides for Codexis Inc
Q1 2025
Codexis Inc
Q4 2024
Codexis Inc
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
CDXS
Country
🇺🇸 United States